SomaLogic, Inc. is a privately held biotechnology company based in Boulder, Colorado.

Interested in potential investment opportunities?

SomaLogic Business News

Roy Smythe, M.D., selected as next CEO of SomaLogic

The SomaLogic Board of Directors announced today that they have selected Roy Smythe, M.D. as the next Chief Executive Officer of SomaLogic. A trained surgeon and former translational scientist, Dr. Smythe joins SomaLogic from Royal Philips, where he served as Chief Medical Officer for Strategy and Partnerships.
read more

SomaLogic licenses GNS Healthcare’s REFS™ technology for analysis of its SOMAscan®-derived proteomic data

SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare’s proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic’s proprietary SOMAscan®-derived protein data sets.
read more

SomaLogic launches new version of SOMAscan® assay

SomaLogic has launched a new version of their proprietary SOMAscan® assay. This new version measures approximately 5,000 unique human protein analytes, almost four times more than its predecessor. The optimized assay format also uses new robotic instrumentation, removing as many manual interventions as possible.
read more

SomaLogic teams with Leeds Centre for Personalised Medicine and Health to deliver SOMAscan® platform in clinical healthcare

SomaLogic announced today the establishment of a framework “Partnership for Personalized Health” with the Leeds Centre for Personalised Medicine and Health (CPMH), to be based in Leeds, UK. This collaboration – the first of its kind – aims to help individuals and professionals enhance health decisions by providing: accurate assessment of the current state and future disease risks; deeper understanding of causal and actionable factors that may drive these risks; reliable monitoring of individuals to understand the effectiveness of interventions.

read more

SomaLogic closes $200M financing round

SomaLogic announced today that it has capped its $200 million funding round, anchored by iCarbonX with substantial investments from Nan Fung Life Sciences and Madryn Asset Management. The successful round will accelerate SomaLogic’s goal of becoming the world’s leading provider of precision digital health insights.

read more